Pediatric Dosing for Dextromethorphan-Guaifenesin
The FDA-approved pediatric dosing for dextromethorphan-guaifenesin combination products is age-based, with dextromethorphan dosed at 2.5-10 mL every 12 hours and guaifenesin at 2.5-10 mL every 4 hours depending on age, though these medications should NOT be used in children under 4 years of age for dextromethorphan and under 2 years for guaifenesin. 1, 2
Age-Based Dosing Guidelines
Dextromethorphan (Extended-Release Formulation)
Based on FDA labeling 1:
- Children under 4 years: Do not use
- Children 4 to under 6 years: 2.5 mL every 12 hours (maximum 5 mL in 24 hours)
- Children 6 to under 12 years: 5 mL every 12 hours (maximum 10 mL in 24 hours)
- Children 12 years and older: 10 mL every 12 hours (maximum 20 mL in 24 hours)
Guaifenesin (Immediate-Release Formulation)
Based on FDA labeling 2:
- Children under 2 years: Consult a physician
- Children 2 to under 6 years: 2.5-5 mL (½ to 1 teaspoonful) every 4 hours
- Children 6 to under 12 years: 5-10 mL (1 to 2 teaspoonfuls) every 4 hours
- Children 12 years and older: 10-20 mL (2 to 4 teaspoonfuls) every 4 hours
- Maximum: Do not exceed 6 doses in 24 hours
Critical Safety Considerations
Avoid codeine-containing medications entirely in children due to risk of serious respiratory distress. 3 The evidence strongly suggests that over-the-counter cough and cold medicines should not be prescribed for acute cough in children until proven to make cough less severe or resolve sooner 3.
Important Caveats
Weight-based dosing variability: Age-based dosing results in substantial variability in mg/kg doses administered. Research suggests doses of 0.35-0.94 mg/kg for dextromethorphan, with potential for improved symptom control at 0.5 mg/kg, though this must be balanced against adverse events 4.
Formulation matters: Extended-release dextromethorphan polistirex has 2-3 times longer duration than standard formulations. A case report documented life-threatening toxicity in a 23-month-old at 71.4 mg/kg with blood concentration of 110 ng/mL 5.
Limited efficacy evidence: Honey may offer more relief for acute cough than dextromethorphan in children 3. Multiple studies show conflicting data on dextromethorphan efficacy, though recent objective monitoring in children aged 6-11 years demonstrated 21-25% reduction in cough frequency compared to placebo 6.
Practical Dosing Algorithm
- Verify age eligibility: Confirm child is ≥4 years for dextromethorphan, ≥2 years for guaifenesin
- Use measuring device provided: Never use household spoons
- Start with lower end of dose range for younger/smaller children within age bracket
- Monitor for adverse effects: Particularly drowsiness, dizziness, GI upset
- Re-evaluate in 2-4 weeks if cough persists to assess for specific etiological pointers 3
The pharmacokinetic data shows that oral clearance and volume of distribution increase with age due to body size, with terminal half-life also increasing 7. This supports the age-based dosing approach, though allometric scaling indicates no maturation-related changes in clearance when adjusted for body size 7.